Radical immune cell 'Reboot' tested for incurable autoimmune conditions
NCT ID NCT07161193
Summary
This early-stage trial is testing a therapy called CD19 CAR-T cells for people with severe autoimmune diseases that haven't improved with standard treatments. It aims to see if this approach, which involves modifying a patient's own immune cells to target and remove harmful B cells, is safe and can control disease activity. The study will enroll 30 adults with one of seven specific, difficult-to-treat autoimmune conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Luoyang, Henan, 471003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.